Repros Therapeutics Inc. (NASDAQ:RPRX) shares were up 16.7% during mid-day trading on Friday . The stock traded as high as $2.20 and last traded at $2.10, with a volume of 1,388,163 shares traded. The stock had previously closed at $1.80.

Separately, Zacks Investment Research lowered Repros Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $21.50.

The firm’s market capitalization is $51.55 million. The firm has a 50 day moving average price of $1.69 and a 200 day moving average price of $1.50.

Repros Therapeutics (NASDAQ:RPRX) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. Analysts predict that Repros Therapeutics Inc. will post ($0.75) earnings per share for the current year.

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include Androxal and Proellex. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.